Expertise in
31
conditions

Dr. Samer S. Kasbari

Hematology
Southeastern Medical Oncology Center
211 Beaman St, 
Clinton, NC 
Accepting New Patients
Offers Telehealth
Referral may be required
Before you request
Expertise in
31
conditions
Southeastern Medical Oncology Center
211 Beaman St, 
Clinton, NC 

Overview

Samer Kasbari is a Hematologist practicing medicine in Clinton, North Carolina.

Dr. Kasbari is highly rated in 31 conditions, according to our data. His clinical expertise encompasses Vitamin B12 Deficiency, Anemia, Non-Hodgkin Lymphoma, Endoscopy, and Bone Marrow Aspiration.

He is actively involved in clinical research, co-authoring 8 peer reviewed articles and participating in 67 clinical trials. Dr. Kasbari is currently accepting new patients.

Specialties

Hematology

Licenses

Internal Medicine in NH

Hospital Affiliations

Unc Health Care Wayne
Ecu Health Medical Center
Rex Hospital
Sampson Regional Medical Center
Vidant Duplin Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
TeamCare
  • OTHER COMMERCIAL
Trillium
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

Southeastern Medical Oncology Center
211 Beaman St, Clinton, NC 28328
Other Locations
Southeastern Medical Oncology Center
203 Cox Blvd, Goldsboro, NC 27534

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

67 Clinical Trials

Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Phase: Phase 3
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: September 04, 2026
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 02, 2026
Intervention Type: Other
Study Phase: Phase 3
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Radiation, Procedure
Study Phase: Phase 3
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Cabozantinib, Ipilimumab, Nivolumab
Study Phase: Phase 3
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Dabrafenib Mesylate, Ipilimumab, Nivolumab, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 3
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab, Sargramostim
Study Phase: Phase 2/Phase 3
A Randomized Phase III Study of Immune Checkpoint Inhibition With Chemotherapy in Treatment-Naive Metastatic Anal Cancer Patients
A Randomized Phase III Study of Immune Checkpoint Inhibition With Chemotherapy in Treatment-Naive Metastatic Anal Cancer Patients
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Biological, Drug
Study Drugs: Carboplatin, Nivolumab, Paclitaxel
Study Phase: Phase 3
View 9 Less Clinical Trials

8 Total Publications

Publisher Correction: Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial.
Publisher Correction: Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial.
Journal: Nature medicine
Published: August 26, 2025
Similar Doctors
Expertise in
39
conditions
Expertise in
39
conditions
Referral may be required

UT MD Anderson Cancer Center

210 Ashville Ave # 408, 
Cary, NC 
 (56.5 miles away)
713-792-6161
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Tapan Kadia is a Hematologist practicing medicine in Cary, North Carolina. Dr. Kadia is highly rated in 39 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Leukemia, Myelodysplastic Syndrome (MDS), Bone Marrow Aspiration, and Bone Marrow Transplant.

Expertise in
31
conditions
Expertise in
31
conditions
Referral may be required

UT MD Anderson Cancer Center

210 Ashville Ave # 408, 
Cary, NC 
 (56.5 miles away)
713-792-6161
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Prithviraj Bose is a Hematologist practicing medicine in Cary, North Carolina. Dr. Bose is highly rated in 31 conditions, according to our data. His clinical expertise encompasses Myelofibrosis, Essential Thrombocythemia, Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant.

Expertise in
30
conditions
Expertise in
30
conditions
Referral may be required

UT MD Anderson Cancer Center

210 Ashville Ave # 408, 
Cary, NC 
 (56.5 miles away)
713-792-6161
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Richard Champlin is a Hematologist practicing medicine in Cary, North Carolina. Dr. Champlin is highly rated in 30 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Graft Versus Host Disease (GvHD), Leukemia, Bone Marrow Transplant, and Bone Marrow Aspiration.

Frequently Asked Questions about Dr. Samer S. Kasbari

How do I make an appointment with Dr. Samer S. Kasbari?

You can book an appointment with Dr. Samer S. Kasbari by calling their office at 910-592-5727. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Samer S. Kasbari a top-rated expert for Vitamin B12 Deficiency?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Samer S. Kasbari is classified as an Distinguished expert for Vitamin B12 Deficiency, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Samer S. Kasbari specialize in?

While Dr. Samer S. Kasbari is a Hematology, they have specific expertise in Vitamin B12 Deficiency, Anemia, and Non-Hodgkin Lymphoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Samer S. Kasbari participate in research or clinical trials?

Yes. Dr. Samer S. Kasbari has published 8 articles and abstracts on conditions like Vitamin B12 Deficiency. You can view a list of Dr. Samer S. Kasbari's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Samer S. Kasbari accept my insurance?

Dr. Samer S. Kasbari accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 910-592-5727 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kasbari's expertise for a condition
ConditionClose
    View All 26 Advanced Conditions
    View All 58 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile